Altium Capital Management LP acquired a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 220,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,194,000.
Several other large investors have also recently made changes to their positions in TBPH. SG Americas Securities LLC acquired a new position in Theravance Biopharma during the second quarter worth $117,000. Citigroup Inc. increased its position in Theravance Biopharma by 57.7% during the second quarter. Citigroup Inc. now owns 9,905 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 3,626 shares during the last quarter. Handelsbanken Fonder AB acquired a new position in Theravance Biopharma during the second quarter worth $196,000. HRT Financial LP acquired a new stake in shares of Theravance Biopharma in the first quarter valued at about $200,000. Finally, XTX Topco Ltd bought a new stake in shares of Theravance Biopharma in the second quarter valued at about $207,000. Institutional investors and hedge funds own 82.11% of the company’s stock.
Shares of TBPH stock traded up $0.21 on Thursday, hitting $8.01. The stock had a trading volume of 6,920 shares, compared to its average volume of 666,440. The firm has a market cap of $588.49 million, a P/E ratio of -1.96 and a beta of 0.82. Theravance Biopharma, Inc. has a twelve month low of $6.10 and a twelve month high of $22.74. The company has a fifty day moving average price of $9.33 and a two-hundred day moving average price of $14.63.
Several research firms recently weighed in on TBPH. Needham & Company LLC cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, September 15th. Robert W. Baird cut their price target on shares of Theravance Biopharma from $10.00 to $7.00 and set a “neutral” rating for the company in a research note on Thursday, September 16th. HC Wainwright cut their price target on shares of Theravance Biopharma from $21.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, September 16th. Zacks Investment Research cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating and set a $7.50 target price for the company. in a research note on Wednesday, September 22nd. Finally, Morgan Stanley cut their target price on shares of Theravance Biopharma from $14.00 to $10.00 and set an “underweight” rating for the company in a research note on Thursday, September 16th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $11.95.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
See Also: What is the operating income formula?
Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH).
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.